Articles On Imugene (ASX:IMU)

At the start of each week, I like to look at ASIC's short position report to find out which shares are being targeted by short sellers. This is because I believe it is well worth keeping a close eye on short interest levels as high level...

This trading week seems to have gotten off to a shaky start so far this Monday. At the time of writing, the S&P/ASX 200 Index (ASX: XJO) has opened the week's trading with an early slide, currently down 0.18%. But let's talk about what...

This week’s Bulls N’ Bears profiled ASX runner is… Imugene. Its share price jumped more than 212 per cent to join other impressive companies including Krakatoa Resources, TechGen Metals and GreenTech Metals.

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.55% to 6976.50. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotif...

ASX health stocks rise in past five days and outpace broader markets Blue chip ResMed slips as US FDA approves weight loss drug Clinical stage immuno-oncology small cap Immutep gains 160%  Morgans healthcare and life sciences expert Iain...

The ASX200 has finished the week, trading down just over half a per cent. All sectors lost ground with the utilities sector the weakest today, down about 1.7 per cent. In the green Explorer Saturn Metals (ASX:STN) is up more than 7...

The ASX has ended the week lower, down 0.55pc on Friday Healthcare Sector remains defiant  Small caps led by medtech names and Lake Johnston lithium hunters   The fickle Aussie sharemarket has given back on Friday all that it has made thi...

Imugene has continued to set the ASX boards alight after revealing it had delivered the first dose of its azer-cel therapy to a patient suffering from “difficult-to-treat” large B-cell lymphoma in the US.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a disappointing decline. At the time of writing, the benchmark index is down 0.55% to 6,976.4 points. Four ASX shares that are not letting that hol...

AVITA jumps after providing bullish guidance Anatara up after holding AGM this morning Imugene doses first patient in its Phase 1b clinical trial using azer-cel   AVITA up on bullish sales forecast Regenerative medicine biotech, AVITA Med...

The Magnis Energy Technologies Ltd (ASX: MNS) share price is ending the week deep in the red. At one stage today, the lithium-ion battery technology and materials company's shares were down as much as 57% to 3.5 cents. They have recovered...

The Imugene Limited (ASX: IMU) share price is continuing its incredible run and charging higher again on Friday. In early trade, the clinical stage immuno-oncology company's shares were up a further 34% to 15 cents. Its shares have since p...

Sydney-headquartered clinical stage immuno-oncology company Imugene (ASX: IMU) has achieved an early milestone with the dosing in the US of the first patient using its recently acquired Azer-cel blood cell therapy. Earlier this year, Imugen...

Imugene (ASX:IMU) reaches a major milestone in its phase 1b clinical trial using azer-cel, dosing its first patient after a successful flagship program in America It’s hoped the phase 1b trial will lead to a registrational trial in 2024,...

Wildcat Resources Ltd (ASX: WC8) shares are back from their trading halt on Friday and sinking into the red. In morning trade, the lithium explorer's shares are down 7.5% to 79 cents. Why are Wildcat shares taking a hit on Friday? This hig...

Wildcat Resources (ASX:WC8) recently hit one-year returns of 2721 per cent In January of 2023, the shares were worth 3 cents Now they’re worth 79 cents High-grade lithium discovered in October and again in November have rapidly p...

Welcome to the end of the week. The ASX is set to trade red with ASX200 futures down 0.07 per cent (5pts) near 8:30 am AEDT on Friday. The US ended in the red overnight, with a week-long green streak abruptly ending. This has been enough...

The ASX has closed higher Healthcare leads sector gains Small caps led by KTA and FG1   The Aussie sharemarket has trimmed the fat off this morning’s substantial gains – at one stage there we were easing past the 7,350 mark and off to th...

The S&P/ASX 200 Index (ASX: XJO) continued its November form this Thursday with another positive day of share market gains. By the closing bell, the ASX 200...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a solid gain. At the time of writing, the benchmark index is up 0.6% to 7,037.5 points. Four ASX shares that are rising more than most today are listed below....

The Wildcat Resources Ltd (ASX: WC8) share price won't be going anywhere on Thursday. That's because the high-flying lithium explorer has requested a trading halt this morning. Why is the Wildcat share price paused from trade? With the com...

The Imugene Limited (ASX: IMU) share price is rising again on Wednesday. At one stage today, the ASX All Ords share was up 27% to 8.4 cents. When the clinical stage immuno-oncology company's shares reached that level, it meant they were up...

The Australian dollar and bond yields slid after the Reserve Bank of Australia lifted the cash rate by 0.25% on Melbourne Cup Day, to 4.35%. It was the first change to the official rate in five months – and the first under new governor Mich...

It was only on Tuesday that we got the latest look at ASX 200 bank share Westpac Banking Corp (ASX: WBC)'s full-year results for FY2023. As we went through at the time, it was a pretty pleasing set of numbers from the ASX 200 bank share. W...

Shortly before Without A Fight crossed the finish line to win the 2023 Melbourne Cup, the Reserve Bank of Australia lifted the cash rate once again – by 25 basis points to 4.35 per cent for November. The decision was in line with expert...

The Westpac Banking Corp (ASX: WBC) share price is having a poor session on Tuesday. In afternoon trade, the banking giant's shares are down 2% to $21.48. Should you buy the Westpac share price dip? The broker community is largely undecide...

The S&P/ASX 200 Index (ASX: XJO) is under pressure ahead of the Reserve Bank's meeting. In afternoon trade, the benchmark index is down 0.4% to 6,967.3 points. Four ASX shares that are falling more than most today are listed below. H...

On Monday, the S&P/ASX 200 Index (ASX: XJO) started the week with a small gain. The benchmark index rose 0.3% to 6,997.4points. Will the market be able to build on this on Tuesday? Here are five things to watch: ASX 200 expected to f...

Warren Buffett is called the Oracle of Omaha for good reason. Atop his phenomenal investing success, the 93-year-old CEO of Berkshire Hathaway (NYSE: BRK.A) is well known for sharing his market acumen with eager disciples across the world....

Owners of Westpac Banking Corp (ASX: WBC) shares will soon be getting their FY23 final dividend payment after the bank released its FY23 report. It was a successful period for the ASX bank share – the business reported a 26% increase in...

The S&P/ASX 200 Index (ASX: XJO) has started the week positively. In afternoon trade, the benchmark index is up 0.3% to 6,998.1 points. Four ASX shares that are rising more than most today are listed below. Here's why they are stormi...

Highlights To date, 34 heavily treated patients administered with CF33-hNIS All treatments have been ascertained tolerable and safe Trial expansion is planned for ten patients with bile duct cancer Shares of Imugene Limited (ASX:...

Imugene has recorded positive early signals from the first phase of its metastatic advanced solid tumour clinical trial evaluating the safety and efficacy of its novel cancer-killing virus known as “Vaxinia”.

A Phase 1 metastatic advanced solid tumours (MAST) trial evaluating the safety and efficacy of novel cancer-killing virus CF33-hNIS (VAXINIA) has delivered positive early signals for immuno-oncology company Imugene (ASX: IMU). The study str...

The Imugene Ltd (ASX: IMU) share price is soaring higher today. Shares in the ASX biotechnology company closed on Friday trading for 4.8 cents. At the time of writing, shares are changing hands for 5.3 cents apiece, up 10.4%. For some con...

PYC to take ADOA drug to human clinical trials Imugene provides update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial Cleo’s CleoDX Triage Test was published in ‘Cancer’ journal   PYC to commence human trials in 2024 after...

The Whispir Ltd (ASX: WSP) share price is shooting the lights out on Monday. The ASX tech share closed on Friday trading for 30 cents. At the time of writing, shares are swapping hands for 48 cents apiece, up a whopping 60%. Here's why inv...

Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for both of the intravenous dose escalation trials of its “Vaxinia” virus.

Imugene has taken a further leap forward in its mission to track down and kill cancer tumours by advancing to the final cohort stages for both of the intravenous dose escalation trials of its “Vaxinia” virus.

Highlights Phase 1 MAST trial has cleared cohort 4 of the IV arm of the monotherapy and IV cohort 2 of combination study. The study is evaluating the safety of VAXINIA, novel cancer-killing virus CF33-hNIS. Next cohort is open in IV a...

Imugene (ASX:IMU) reaches the next cohort in the IV arm of its monotherapy dose escalation study, and also its combination study for the cancer-killing virus, Vaxinia As a result, cohort five of the IV arm for the monotherapy dose escala...

Clinical-stage immuno-oncology company Imugene (ASX: IMU) has announced that its Phase 1 MAST (metastatic advanced solid tumours) trial evaluating the safety of novel cancer-killing virus CF33hNIS (VAXINIA) has cleared cohort 4 of t...

ASX-listed medtech Imugene has dosed the first patient with its novel immunotherapy drug candidate “onCARlytics” which has the potential to target and eradicate solid tumours.

Althea’s cannabis oil approved for reimbursement in Ireland Imugene dosed first patient in onCARlytics Phase 1 trial on solid tumours   Althea’s cannabis oil approved for reimbursement Cannabis company Althea Group (ASX:AGH) has announced...

Imugene (ASX:IMU) has announced that its CD19 oncolytic virotherapy drug candidate, onCARlytics, has commenced a Phase 1 clinical trial, with the first patient now dosed.

Imugene is poised to secure further development opportunities for its “super-charged” cell immunotherapy programs after putting them on show at what it says is the world’s most influential oncology platform.

Imugene (ASX:IMU) announces that its B cell immunotherapy, HER-Vaxx, and CF33 oncolytic virotherapy CHECKVacc are being showcased at the ESMO Congress this week in Madrid IMU is a clinical-stage immuno-oncology company, that aims to cont...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

The US FDA has stamped Imugene as the exclusive sponsor for its allogeneic “azer-cel” cancer treatment after transferring an investigational new drug application to the company from Precision Biosciences.

The US Food and Drug Administration (FDA) has transferred an investigational new drug (IND) application for allogeneic CD19 CAR T azer-cel from Precision Biosciences Inc to Imugene (ASX: IMU). The transfer follows Imugene’s acquisition of a...